Clinical Trial Search

Primary: Changes in Log-transformed Urinary Albumin-to-creatinine Ratio (UACR) at Week 12 — -0.10; -0.15; -0.53 Log(mg/g) — p=0.7953

Primary: Parts 1, 2, 4, and 5: Number of Participants Who Experienced Dose-limiting Toxicities (DLTs) — 1; 1; 1; 2 Participants

Primary: Percentage of Participants With Overall Survival (OS) — 47.9; 26.6 percentage of participants — p=0.0001

Primary: Subjects Achieving 50% or Greater Psoriasis Area and Severity Index (PASI) Reduction — 2; 2 Participants

Primary: The Percentage Change in Palmoplantar Pustulosis Area and Severity Index (PPP ASI) at Week 16 From Baseline — -33.6; -44.2; -48.3; -46.2 Percentage of change in PPP ASI…

Primary: Change of Serum Creatinine — 0.92; 0.70 mg/dL

Primary: Number of Participants With Evidence of Cortical Bridging for Fracture Healing — 9; 8 Participants

Primary: Number of Subjects With Any Solicited Local Adverse Events (AEs) During a 7-day Follow-up Period After the First Vaccination (Administered at Day 1) — 5; 6; 0; 22…

Primary: Change in Score of Patient Health Questionnaire-9 — -8.7; -5.5 score on a scale

Primary: Treatment Response — 14; 13 Participants

Primary: Response Rate (RR) Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 — 3; 15; 5 Participants

Primary: Number of Participants With a Response Defined as Change in IGA-C (Investigators Global Assessment) Score by at Least 2 Ordinals From Baseline to Week 4 — 2; 0; 1…

Primary: Change From Baseline in Inflammatory Lesion Counts at Week 12 — 22.3; 19.0 inflammatory lesions

Primary: Number of Participants With VGPR or Better Response to Induction — 6 Participants — p=0.597

Primary: Change in Binge Eating Sum Score — -0.60; 0.89 score on a scale